ATF4 and glioma: A two‐gene prognosis risk model revealed that, compared to patients with lower co‐expression, those with higher co‐expression of ATF4 and NF‐κB2 showed a significantly stronger correlation with worsened relapse, metastasis, and reduced overall survival in patients with breast cancer (Figure 6L–N), ACC, osteosarcoma, glioma, and KIRC (Figure S4H–K, Supporting Information).